TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Invenra Inc. and Astellas Pharma Forge Strategic Research Partnership in Therapeutic Bispecific Antibody Discovery

Wednesday, April 10, 2024

Invenra Inc., an innovative leader in bispecific antibody technology, is excited to announce a strategic research partnership with Astellas Pharma, a global pharmaceutical company focused on delivering value to patients through innovative science. This collaboration will utilize Invenra’s advanced B-Body® bispecific antibody platform to support Astellas’ targeted research and development efforts.

As part of the agreement, Astellas will gain access to Invenra’s B-Body technology, advancing their exploration into bispecific therapeutics. Following the research phase, Astellas will have the option to negotiate future licensing agreements.

Dr. Roland Green, CEO of Invenra, expressed his enthusiasm, stating, “We are honored to collaborate with Astellas, a leader in therapeutic development. We believe this partnership holds great promise for delivering meaningful benefits to patients.”

Both companies share a commitment to advancing healthcare through scientific research, with the ultimate goal of providing innovative treatments to patients worldwide.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement SummitHealthcare Innovation & Transformation Summit